278 related articles for article (PubMed ID: 17986163)
1. Complicated pain management in a CYP450 2D6 poor metabolizer.
Foster A; Mobley E; Wang Z
Pain Pract; 2007 Dec; 7(4):352-6. PubMed ID: 17986163
[TBL] [Abstract][Full Text] [Related]
2. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.
Susce MT; Murray-Carmichael E; de Leon J
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.
de Leon J; Dinsmore L; Wedlund P
J Clin Psychopharmacol; 2003 Aug; 23(4):420-1. PubMed ID: 12920424
[No Abstract] [Full Text] [Related]
6. CYP2D6 in the metabolism of opioids for mild to moderate pain.
Leppert W
Pharmacology; 2011; 87(5-6):274-85. PubMed ID: 21494059
[TBL] [Abstract][Full Text] [Related]
7. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.
Reynolds KK; Ramey-Hartung B; Jortani SA
Clin Lab Med; 2008 Dec; 28(4):581-98. PubMed ID: 19059064
[TBL] [Abstract][Full Text] [Related]
8. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
9. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.
Zwisler ST; Enggaard TP; Noehr-Jensen L; Pedersen RS; Mikkelsen S; Nielsen F; Brosen K; Sindrup SH
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):335-44. PubMed ID: 19281600
[TBL] [Abstract][Full Text] [Related]
10. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.
Haufroid V; Hantson P
Clin Toxicol (Phila); 2015 Jul; 53(6):501-10. PubMed ID: 25998998
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
[TBL] [Abstract][Full Text] [Related]
13. Observations on the urine metabolic profile of codeine in pain patients.
Yee DA; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Mar; 38(2):86-91. PubMed ID: 24396053
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
O'Connor AB; Zwemer FL; Hays DP; Feng C
Acad Emerg Med; 2009 Jun; 16(6):477-87. PubMed ID: 19426295
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or antidepressant therapy in chronic non-cancer pain.
Manchikanti L; Manchikanti KN; Pampati V; Cash KA
Pain Physician; 2009; 12(1):259-67. PubMed ID: 19165308
[TBL] [Abstract][Full Text] [Related]
16. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
[TBL] [Abstract][Full Text] [Related]
17. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
[TBL] [Abstract][Full Text] [Related]
18. Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer.
Voronov P; Przybylo HJ; Jagannathan N
Paediatr Anaesth; 2007 Jul; 17(7):684-7. PubMed ID: 17564651
[TBL] [Abstract][Full Text] [Related]
19. The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption.
Candiotti KA; Yang Z; Rodriguez Y; Crescimone A; Sanchez GC; Takacs P; Medina C; Zhang Y; Liu H; Gitlin MC
Pain Med; 2009; 10(5):799-805. PubMed ID: 19523031
[TBL] [Abstract][Full Text] [Related]
20. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
Zahari Z; Ismail R
Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]